Clinical and pharmacological group: & nbsp

Antineoplastic hormonal agents and hormone antagonists

Included in the formulation
  • Fazlodex ®
    solution w / m 
    AstraZeneca AB     Sweden
  • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    ONLS

    АТХ:

    L.02.B.A.03   Fulvestrant

    Pharmacodynamics:Competitively binds to estrogen receptors without showing its own estrogen-like activity, it blocks the trophic action of estrogens by suppressing the activity of estrogen receptors followed by their degradation. It also reduces the expression of progesterone receptors.

    It does not stimulate the endometrial cells of women in meno- and postmenopausal women. Does not affect the metabolism of bone tissue.

    Pharmacokinetics:After intramuscular injection, the maximum concentration in the blood plasma is achieved after 7 days. The connection with plasma proteins is 99%.

    Metabolism in the liver.

    The half-life period is 50 days. Elimination with feces in the form of inactive metabolites.

    Indications:It is used to treat locally advanced or disseminated breast cancer with positive estrogen receptors in postmenopausal women with progression on or after anti-estrogen therapy.

    II.C50   Malignant neoplasm of breast)

    Contraindications:Dysfunction of the liver, individual intolerance.

    Carefully:Expressed violations of kidney function (creatinine clearance less than 30 ml per minute), hypersensitivity, children under 18 years.

    Pregnancy and lactation:

    The recommendation category is FDA - D. Contraindicated in pregnancy and lactation.

    Dosing and Administration:Intramuscularly, 250 mg per day once a month.

    The highest daily dose: 250 mg.

    The highest single dose: 250 mg.

    Side effects:

    Central and peripheral nervous system: headache, asthenia.

    The cardiovascular system: hot flashes (sensation of fever), thromboembolism.

    Digestive system: nausea, vomiting, anorexia.

    Dermatological reactions: a rash.

    Urinary system: urinary tract infections.

    Reproductive system: galactorrhea, leukorrhea, vaginal bleeding, vaginal moniliasis.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    Fulvestrant should not be mixed with other medications.

    Special instructions:

    It is advisable to use caution when driving vehicles and working with moving mechanisms.

    Instructions
    Up